Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Diabetes Care

• Publication date

  1996-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/diacare.19.2.151PMID 8718436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

  1995cited by this paper
• Insulin Resistance or Insulin Deficiency: Which Is the Primary Cause of NIDDM?

  1994cited by this paper
• Troglitazone Prevents Glucose-Induced Insulin Resistance of Insulin Receptor in Rat-1 Fibroblasts

  1994cited by this paper
• Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat

  1994cited by this paper
• Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells.

  1994cited by this paper
• Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance.

  1994cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• Antihypertensive effects of CS-045 treatment in obese Zucker rats.

  1993cited by this paper
• Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

  1992cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper
• A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.

  1991cited by this paper
• Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM

  1991cited by this paper
• Studies on hindered phenols and analogues. IV, Formation of 3,9-dioxabicyclo[4.3.1]decanes and its application for antidiabetic agents

  1991cited by this paper
• In vitro studies on the action of CS-045, a new antidiabetic agent.

  1990cited by this paper
• Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.

  1989cited by this paper
• Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

  1988cited by this paper

• Factors Affecting the Treatment Heterogeneity of PPARγ and Pan-PPAR Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Machine Learning-Based Meta-Regression Analysis

  2026cites this paper
• PPAR-γ in Melanoma and Immune Cells: Insights into Disease Pathogenesis and Therapeutic Implications

  2025cites this paper
• Current opportunities for the prevention and treatment of carbohydrate metabolism disorders

  2024cites this paper
• Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

  2020cites this paper
• Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease.

  2020cites this paper
• Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances.

  2019cites this paper
• Plaque imaging to refine indications for emerging lipid-lowering drugs

  2017cites this paper
• 53 : Antidiabetics and Hypoglycemics

  2017cites this paper
• Études in vivo et in vitro sur le potentiel néphroprotecteur de plantes médicinales anti-diabétiques de la pharmacopée traditionnelle des Cris de la Baie-James

  2016cites this paper
• Targets to treat metabolic syndrome in polycystic ovary syndrome

  2015cites this paper
• Insulin Sensitivity in Adipose and Skeletal Muscle Tissue of Dairy Cows in Response to Dietary Energy Level and 2,4-Thiazolidinedione (TZD)

  2015cites this paper
• Chromium Picolinate and Biotin Supplementation May Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus

  2015cites this paper
• Part of the Special Issue: Metabolism 2014 - Alterations of metabolic pathways as therapeutic targets Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): a review

  2014cites this paper
• Synthesis and antihyperglycemic evaluation of new 2-hydrazolyl-4-thiazolidinone-5-carboxylic acids having pyrazolyl pharmacophores.

  2014cites this paper
• Frequency of Fat Mass and Obesity-Associated Gene rs9939609 and Peroxisome Proliferator-Activated Receptor Gamma 2 Gene rs1801282 Polymorphisms among Trinidadian Neonates of Different Ethnicities and Their Relationship to Anthropometry at Birth

  2014cites this paper
• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review

  2014cites this paper
• Topical Rosiglitazone Is an Effective Anti-Scarring Agent in the Cornea

  2013cites this paper
• Cardiometabolic interventions - focus on transcriptional regulators.

  2013cites this paper
• Recent Pharmacological Developments on Rhodanines and 2,4-Thiazolidinediones

  2013cites this paper
• Troglitazone

  2012cites this paper
• Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.

  2012cites this paper
• Strategies for Better Diabetes Control in the US

  2012cites this paper
• Management and treatment of diabetes mellitus.

  2012cites this paper
• PPARG and ADIPOQ gene polymorphisms increase type 2 diabetes mellitus risk in Asian Indian Sikhs: Pro12Ala still remains as the strongest predictor.

  2010cites this paper
• Fulminant Hepatitis

  2010cites this paper
• Metformin for the Treatment of Polycystic Ovary Syndrome (PCOS)

  2009cites this paper
• Biennial review of infertility

  2009cites this paper
• Weight management and chronic disease

  2009cites this paper
• VHRM-4053-Safety and efficacy of rosiglitazone in the elderly

  2009cites this paper
• Safety and efficacy of rosiglitazone in the elderly diabetic patient

  2009cites this paper
• Rosiglitazone Maleate and Metformin Hydrochloride in Fixed Combination: What Role in the Treatment of Type 2 Diabetes?

  2009cites this paper
• The impact of diabetes mellitus on coronary artery disease: new therapeutic approaches.

  2009cites this paper
• Vascular Effects of Diabetes Mellitus

  2009cites this paper
• Oral hypoglycaemic drugs and newer agents use in Type 2 diabetes mellitus

  2008cites this paper
• Susceptibilidade genética e outros fatores de risco associados ao sobrepeso e à obesidade em populações afro-descendentes do Vale do Ribeira-SP

  2008cites this paper
• Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.

  2008cites this paper
• Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice.

  2008cites this paper
• Type 2 diabetes and oral antihyperglycemic drugs.

  2008cites this paper
• The Effect of PPARα, PPARδ, PPARγ, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice

  2007cites this paper
• Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review.

  2007cites this paper
• Indicators for the Efficacy of Pioglitazone Before and During Treatment in Japanese Patients with Type 2 Diabetes

  2007cites this paper
• Comparison of the antidiabetic effects of brain‐derived neurotrophic factor and thiazolidinediones in obese diabetic mice

  2007cites this paper
• Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone

  2006cites this paper
• Le syndrome métabolique : mythes et réalités

  2006cites this paper
• Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.

  2006cites this paper
• Long-term Effect of Pioglitazone Treatment in Patients with Type 2 Diabetes

  2006cites this paper
• Evidence-based Guideline by the German Diabetes Association and the German Geriatric Society Diagnosis , Treatment and Follow-up of Diabetes mellitus in the Elderly

  2006cites this paper
• Evidence-based Guideline by the German Diabetes Association and the German Geriatric Society

  2006cites this paper
• Effects of Pro12Ala polymorphism of peroxisome proliferator‐activated receptor γ2 gene on rosiglitazone response in type 2 diabetes

  2005cites this paper
• Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.

  2005cites this paper
• Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician

  2005cites this paper
• Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study.

  2005cites this paper
• The peroxisome proliferator activated receptorφ2 (PPARφ2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients

  2005cites this paper
• Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.

  2005cites this paper
• The peroxisome proliferator activated receptorgamma2 (PPARgamma2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients.

  2005cites this paper
• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

  2004cites this paper
• Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter

  2004cites this paper
• Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

  2004cites this paper
• Therapy of Type 2 Diabetes Mellitus

  2004cites this paper
• The effects of oral anti‐hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes

  2004cites this paper
• Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways.

  2004cites this paper
• Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone

  2004cites this paper
• Managing pediatric ingestions of the new antidiabetic agents.

  2004cites this paper
• The BBZDR/Wor rat model for investigating the complications of type 2 diabetes mellitus.

  2004cites this paper
• A Comparison of Agents Used to Manage Type 2 Diabetes Mellitus

  2004cites this paper
• Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.

  2003cites this paper
• Hypertension and nephropathy.

  2003cites this paper
• Insulin, glucagon, and hypoglycemic drugs

  2003cites this paper
• Therapeutic efficacy and factors that affect response of rosiglitazone in insulin-resistant type 2 diabetes

  2003cites this paper
• PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?

  2003cites this paper
• Weight Effect of Current and Experimental Drugs for Diabetes Mellitus

  2003cites this paper
• Insulin sensitizers.

  2003cites this paper
• The independent effects of purified EPA and DHA supplementation on cardiovascular risk in treated-hypertensive type 2 diabetic individuals

  2003cites this paper
• Stage of Change Advancement for Diabetes Self-Management Behaviors and Glucose Control

  2003cites this paper
• The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.

  2003cites this paper
• Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.

  2003cites this paper
• Tiazolidinedionas. Beneficios y riesgos reales

  2002cites this paper
• The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

  2002cites this paper
• Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives.

  2002cites this paper
• Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus.

  2002cites this paper
• Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.

  2002cites this paper
• Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

  2002cites this paper
• The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin

  2002cites this paper
• New trends in the development of oral antidiabetic drugs.

  2002cites this paper
• Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

  2002cites this paper
• Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population.

  2002cites this paper
• Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.

  2002cites this paper
• Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.

  2002cites this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cites this paper
• Thiazolidinediones: A Review of Their Benefits and Risks

  2002cites this paper
• Cyotomedical therapy for insulinopenic diabetes using microencapsulated pancreatic beta cell lines.

  2002cites this paper
• Differentiating members of the thiazolidinedione class: a focus on safety

  2002cites this paper
• Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.

  2002cites this paper
• Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone.

  2002cites this paper
• Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.

  2001cites this paper
• Effects of high-dose troglitaz one on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits.

  2001cites this paper
• Objetivos y estrategia teraputica en la diabetes mellitus tipo 2

  2001cites this paper
• Proyecto COMBO: Criterios y pautas de terapia combinada en la diabetes tipo 2. Documento de consenso (y II)

  2001cites this paper
• Effects of high-dose troglitazone on insulin sensitivity and β-cell function in watanabe heritable hyperlipidemic rabbits

  2001cites this paper
• Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes.

  2001cites this paper